INTRODUCTIONIn the health plan year 2025, health care stakeholders faced the lingering effects of the COVID-19 pandemic, a change in presidential and congressional party leadership, and artificial intelli­gence (AI)’s growing integration in health care. In addition, the rapid growth of the GLP-1 drug category overshadowed the im­pact of biologic-based products, especially cancer therapeutics.These market factors […]

Author